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Introduction: High local control rates are reported after stereotactic
ablative body radiotherapy (SABR) in stage I non-small cell lung
cancer. Toxicity is uncommon, but few reports on long-term fol-
low-up are available. We studied the incidence of chest wall pain
(CWP) and rib fractures in patients with long-term follow-up.
Methods: Between 2003 and 2009, 500 patients (530 tumors)
underwent SABR using risk-adapted fractionation schemes, consist-
ing of three fractions of 20 Gy, five fractions of 12 Gy, or eight
fractions of 7.5 Gy. Toxicity data were collected in a prospective
database and scored using Common Terminology Criteria for Ad-
verse Events (CTCAE) version 4.03. Chest wall volumes receiving
doses of 30, 40, 45, and 50 Gy (V30 Gy–V50 Gy) and maximum
dose in 2 cm3 of chest wall (D2 ml) were determined for patients
with CWP or rib fractures (n  57).
Results: With a median follow-up of 33 months, the 3-year overall
survival and local control rates were 53.1% and 90.4%, respectively.
CWP developed in 11.4% of patients and was severe (grade 3) in
2.0%. Rib fractures were observed in eight patients (1.6%), accom-
panied by CWP in seven of these patients. On multivariate analysis,
patients with CWP had larger treatment volumes and shorter tumor-
chest wall distances, whereas patients with rib fractures had larger
tumor diameters and treatment volumes. Grade 3 CWP and rib
fractures were associated with larger volumes of chest wall receiv-
ing doses of 30 to 50 Gy and rib fractures specifically with a higher
maximum dose in the chest wall.
Conclusions: Severe (grade 3) chest wall toxicity is uncommon
after risk-adapted SABR and manifests in 2% or fewer of patients.
Key Words: Early-stage non-small cell cancer, Stereotactic ablative
radiotherapy, Toxicity, Chest wall pain, Rib fracture.
(J Thorac Oncol. 2011;6: 2052–2057)
Local control rates exceeding 90% have been reported usingstereotactic ablative body radiotherapy (SABR) for stage I
non-small cell lung cancer (NSCLC).1,2 These encouraging
results, achieved mainly in medically inoperable patients,
were accompanied with limited normal tissue toxicity.3 As
SABR is increasingly being used in fitter populations with
fewer competing causes of mortality,4 the population at risk
for late normal tissue toxicity will increase. Severe SABR-
related toxicity is observed in less than 5% of patients,3,5 with
most cases due to grade 3 pneumonitis and rib fractures.
However, concerns have been expressed that the true extent
of late toxicity may be underestimated as long-term follow-up
of large patient cohorts has not yet been reported.6
SABR was introduced at the VU University Medical
Center in 2003, and to date, more than 700 patients with
early-stage NSCLC have undergone this treatment. The pur-
pose of this study is to characterize the incidence of, and
identify risk factors for, chest wall pain (CWP) and rib
fractures in a large patient cohort with long follow-up.
PATIENTS AND MATERIALS
Patient Selection and Evaluation
Details of all patients treated for early-stage NSCLC
using SABR at our center are entered into a prospective
database. To select patients with sufficiently long follow-up
to assess late toxicity, only patients who underwent SABR
between 2003 and 2009 were included, and all were treated
using fixed-beam techniques.
In total, 500 eligible patients were treated for 530 stage
I tumors between April 2003 and April 2009. All patients had
a diagnosis of stage I NSCLC based on the combination of
histological confirmation (36.4%), local uptake on the 18F-
fluorodeoxyglucose positron emission tomography scan
(99.6%), and having a new or growing lesion on chest
computed tomography (CT) scan (99.6%). Of these, 75% of
patients were judged to be medically inoperable by a multi-
disciplinary tumor board, and 25% declined surgery. Table 1
summarizes the relevant patient and tumor characteristics of
the study population, which comprised 291 males and 209
females with a median age of 74 years at presentation.
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Treatment Planning
Details of target definition, treatment planning, and risk-
adapted fractionation schemes used at our center have been
described previously.5 Briefly, 4D-CT scans were performed
during uncoached free breathing and used to generate individu-
alized internal target volumes that encompass tumor positions
during all phases of respiration. A three-dimensional margin of
3 mm is added to the internal target volume to derive a planning
target volume (PTV), and all patients underwent online posi-
tioning including orthogonal imaging using the ExacTrac sys-
tem and 6D robotic couch system (BrainLab, Feldkirchen, Ger-
many). Treatment planning was performed with Brainscan
software using a pencil-beam algorithm (Brainscan v. 5.2, Brain-
Lab Inc., Feldkirchen, Germany) using 8–12 non-coplanar static
beams aimed at the target volume using high-definition multileaf
collimation. All plans were individually optimized to avoid hot
spots in the chest wall, mediastinum, or lung hilus.
Risk-adapted fractionation schemes were used: three
fractions of 20 Gy for T1 lesions not adjacent to the chest
wall; five fractions of 12 Gy for T1 lesions showing broad
contact with the chest wall, as well as for all T2 lesions; or
eight fractions of 7.5 Gy for central lesions. All doses were
prescribed to the PTV encompassing 80% isodose. The cal-
culated biologically effective doses (BED/10Gy) for tumor
at the prescription isodose were 180 Gy10, 132 Gy10, and 105
Gy10, respectively, for the three-, five-, and eight-fraction
schemes.
Follow-Up
Routine follow-up consisted of visits after 3, 6, 12, 18,
and 24 months and yearly thereafter. At each follow-up visit,
new symptoms were recorded, and a diagnostic CT scan was
performed. Of the patients who were alive at 3 months, CT
scans were available in 86.2% of cases, with corresponding
figures at 6 months in 86.6%, at 12 months 83.4%, at 18
months 58.3%, at 24 months 63.4%, and at 36 months 36.9%.
The increase in patients with missing CT data on follow-up
was primarily due to the fact that many patients were referred
for SABR from other regions of the Netherlands. In view of
the advanced age and relatively poor condition of our patient
population, a high proportion of patients were followed
through visits to their pulmonology outpatient clinics at
longer follow-up duration. Details of these patients were
obtained from their referring institutions.
Toxicity data were scored according to the Common Toxic-
ity Criteria for Adverse Events version 4.037 (Table 2). Toxicity
manifesting within 3 months of SABR was defined as early-
onset toxicity and that seen after 3 months as late-onset
toxicity. Rib fractures were independently documented by
radiologists, either on a chest radiograph or CT scan of the
thorax. CWP or rib fractures were not scored if secondary to
tumor recurrence, impossible to be linked to the SABR (e.g.,
pain right lower lobe with a tumor in the left upper lobe), or
explained by other medical conditions.
The closest distance between the edge of the tumor and
the chest wall (tumor-chest wall distance) was measured in an
end-inspiration phase of the planning 4D-CT. Several reports
on chest wall toxicity have defined patients at risk for CWP
and rib fractures if they had tumors within 20 to 25 mm of the
chest wall. For comparison purposes, the incidence of toxicity
was separately reported for patient at risk with tumors within
25 mm of the chest wall.
Dosimetric Evaluation of Chest Wall Doses
A more detailed evaluation of chest wall doses was
performed in 57 patients who experienced CWP and/or rib
fractures. The chest wall was defined by an expansion of the
lungs with 2 cm in lateral, posterior, and anterior directions
except in the direction of the mediastinum, with inclusion of
intercostal muscles but excluding other muscles and skin.8
Based on previous reports in the literature,9–13 the chest wall
volumes (in cm3) receiving doses of 30 Gy (V30), 40 Gy
(V40), 45 Gy (V45), 50 Gy (V50) and the dose in 2 cm3 of
the chest wall (D2 ml) were determined.
The biological impact of radiation is dependent of the
total dose, the dose per fraction, and the tissue sensitivity for
radiation (/ ratio). In conventional fractionated radiother-
apy, the linear quadratic model (LQ model) is used to convert
TABLE 1. Patient and Tumor Characteristics (N  500)
Characteristics n (% or Range)
Age (yr) 74 (42–92)
Gender
Male 291 (58.2)
Female 209 (41.8)
PTV (ml), median 24 (3–220)
T-stage per tumora (n  530)
T1N0 307 (57.9)
T2N0 223 (42.1)
Histology
Not obtained 318 (63.6)
NSCLCb 182 (36.4)
Reason for referral
Medically inoperable 374 (74.8)
Refused surgery 126 (25.2)
Fractionation scheme (n  530)
3  20 Gy 215 (40.6)
5  12 Gy 226 (42.6)
8  7.5 Gy 89 (16.8)
Follow-up (mo), median 33 (13–86)
a TNM staging 6th edition.
b NSCLC: 33.5% adenocarcinoma, 31.3% squamous cell carcinoma, 35.2%
NSCLC not otherwise specified.
PTV, planning target volume; NSCLC, non-small cell lung cancer; TNM, tumor
node metastasis.
TABLE 2. Chest Wall Pain Grading System
Grade
Definition According
to CTCAE
Corresponding Pain
Medication
1 Mild pain No pain medication needed
2 Moderate pain, limiting
instrumental daily activities
Use of nonopioid pain
medication
3 Severe pain, limiting self-care Use of opioids
No grades 4–5 are defined in CTCAE version 4.03.
CTCAE, Common Terminology Criteria for Adverse Events.
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different schedules to a biological equivalent dose for tumor
and normal tissue (BED): BED  dose  (1  [dose per
fraction/?/?]).
Although the LQ model is considered less valid when
fraction sizes exceed 8 Gy, no generally accepted model is
available for stereotactic fractionation sizes. To be able to
compare the different fractionation schemes, we converted
the five- and eight-fraction schedules used toward the equiv-
alent dose for three fractions of 20 Gy using the LQ model.
The three-fraction schedule was set as benchmark and an /
ratio of 3 used for late chest wall toxicity.14
Statistical Analysis
Statistical analyses were conducted using SPSS soft-
ware package version 15 (SPSS Inc., Chicago, IL). Median
follow-up was determined for patients who were alive, and
patients who died were censored in analysis. Actuarial rates
of local control, survival, and toxicity were calculated with
Kaplan-Meier algorithms using the first day of treatment as
starting point. Comparison between groups for categorical
variables was performed using a 2 test. Continuous variables
were assessed using independent sample t tests. Statistical
significant variables in univariate analysis were assessed in
multivariate analysis. Clinical factors analyzed were age,
gender, chronic obstructive pulmonary disease (COPD) sta-
tus, World Health Organization performance status, and
Charlson comorbidity index. Tumor and treatment factors
included in the analysis were the tumor diameter, PTV
volume, tumor-chest wall distance, fractionation scheme, and
tumor node metastasis stage.
RESULTS
The median follow-up of patients who were alive was
33 months (range, 13–86 months). The local control rate and
overall survival rates were 90.4% and 53.1%, respectively, at
3 years. The median PTV was 24 cm3 (range, 3–220 cm3).
Chest Wall Toxicity
Toxicity results are summarized in Table 3. CWP was
reported in 57 patients (11.4%) and was scored as grade 3
(severe) in 10 patients (2.0%). Early onset of CWP was
defined as that manifesting within 3 months of the start of
SABR, and this manifested in 32 patients (6.4%) and was
scored as grade 3 in five patients (1%). Late-onset CWP was
reported in 25 patients (5.0%), with the median time of onset
being 8 months post-SABR (range, 4–24 months). Late-onset
CWP was classified as grade 3 in five patients (1%). Pain
relief was documented in 24.6% in patients with any grade of
CWP and in 20% in patients who developed severe CWP. Rib
fractures developed in eight patients, at a median time of 24
months (range, 6–27 months), with seven of the eight report-
ing CWP. However, only two patients with rib fractures
developed grade 3 CWP. Figure 1 shows the actuarial cumu-
lative incidence of grade 3 CWP and rib fractures, with the
3-year rate of grade 3 CWP and rib fracture rates being 2.2%
and 2.7%, respectively.
Analysis of Risk Factors for Chest Toxicity
Univariate analysis showed a significant difference in
tumor-to-chest wall distance, tumor diameter, and treatment
volume (PTV) in patients with CWP versus no CWP (Table
4) (p  0.01). Patients with CWP had smaller tumor-to-chest
wall distances, larger tumor diameters, and larger treatment
volumes. Patients manifesting grade 3 pain were significantly
younger than patients without severe pain, with the respective
ages being 65 and 73 years (p  0.01). Patients who devel-
oped rib fractures also had significantly smaller tumor-chest
wall distances (p  0.01). The fractionation scheme was not
a significant risk factor for chest wall toxicity. Although the
five-fraction scheme did appear to show a higher incidence,
this group also had a larger proportion tumors located within
25 mm of the chest wall (91.6%) compared with patients in
the three-fraction (85.5%) and the eight-fraction schemes
(71.4%) (p  0.05). The Charlson comorbidity score, perfor-
mance score, and COPD did not significantly differ between
the groups (data not shown).
Grade 3 CWP was only seen in patients whose tumors
were located within 25 mm of the chest wall, and rib fractures
occurred exclusively in tumors located within 5 mm of the
chest wall. In addition, more than 90% of patients manifest-
ing any degree of CWP had a tumor-to-chest wall distance of
less than 25 mm. In an analysis on patients who were
FIGURE 1. Kaplan-Meier curve showing the cumulative in-
cidence of developing severe chest wall pain (CWP grade 3)
and rib fractures in 500 patients. The median follow-up of
patients alive is 33 months.
TABLE 3. Chest Wall Toxicity Reported After SABR
Early-Onset Toxicity,
n (%)
Early-Onset Toxicity,
n (%)
CWP
Grade 1–2 27 (5.4) 20 (4.1)
Grade 3 5 (1.0) 5 (1.0)
Rib fractures — 8 (1.6)
Chest wall toxicity (CTCAE v4.03) based on number of patients and as a percentage
of study population (n  500). Toxicity manifesting within 3 mo post-SABR was
graded as early onset and after 3 mo as late onset. Seven of the eight patients with rib
fractures also experienced CWP.
SABR, stereotactic ablative body radiotherapy; CWP, chest wall pain; CTCAE,
Common Terminology Criteria for Adverse Events.
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considered to be “at risk” for chest wall toxicity, as defined
by having tumors within 25 mm of the chest wall (n  428,
85.6%), the incidence of CWP, severe CWP, and rib fractures
was 12.0%, 2.3%, 1.9%, respectively.
Multivariate analysis shows significant differences for
patients developing CWP on tumor-chest wall distance (p 
0.05), PTV (p  0.01), and age (p  0.01). A larger PTV
(p  0.01) and younger age (p  0.05) were significantly
different for grade 3 CWP and larger PTV (p  0.01) and
tumor diameter (p  0.05) in patients with rib fractures.
Dosimetric Analysis
The BED corrected dose received by the chest wall
showed a trend toward higher volumes receiving a specific
dose on all dose levels (V30–50 Gy) in patients who devel-
oped have grade 3 CWP and an even higher volume in
patients with rib fractures (Figure 2). Furthermore, the max-
imum dose in the chest wall was higher in patients with rib
fractures. However, these differences were not statistically
significant on univariate analysis (data not shown).
DISCUSSION
This study represents the largest number of patients
analyzed for the incidence of chest wall toxicity after SABR
for stage I NSCLC. The incidence of CWP was 12%, with
nearly 50% of symptomatic patients (6.4%) presenting within
3 months after SABR and the remaining occurring up to 2
years post-SABR. Reassuringly, severe pain requiring opi-
oids was observed in only 2.2% of all patients. Rib fractures
were uncommon, particularly if tumors were located more
than 5 mm from the chest wall.
Others have reported rates of CWP varying from 6 to
25%.9,11,12,15 However, severe pain syndromes were reported
in only approximately 1% of patients.9,11,12 In previous re-
ports on patients with tumors within 20 to 25 mm of the chest
wall, rib fractures were reported in up to 21%.9,12,13,15 Find-
ings of this study are comparable to this literature, even
though only one other publication included more than 100
patients who were followed up for 19 months.9
Any discussion on CWP post-SABR in stage I NSCLC
must also consider comparable toxicity after surgery. Post-
thoracotomy pain syndromes after lobectomy occurs in about
50% of patients,16 with 30% of patients still experiencing
pain after 4 to 5 years.17 Although the majority have mild to
FIGURE 2. Mean and 25th and 75th percentile of volume
of the chest wall receiving 30 Gy (V30 Gy), 40 Gy (V40 Gy),
45 Gy (V45 Gy), and 50 Gy (V50 Gy) and the maximum
dose in 2 cm3 of the chest wall for patients with chest wall
pain (CWP) (in purple, n  57), patients with severe CWP
(CWP grade 3) (in green, n  10), and patients with rib
fractures (in black, n  8).
TABLE 4. Univariate Analysis of Potential Risk Factors for Chest Wall Pain (CWP)
No Pain
n (% or Range)
CWP (Any Grade) Severe CWP (Grade 3) Rib Fractures
n (% or Range) p n (% or Range) p n (% or Range) p
Patients in group (n) 443 57 10 8
Gender
Men 258 (58.2) 33 (57.9) 0.960 3 (30) 0.068 6 (75) 0.331
Women 185 (41.8) 24 (42.1) 7 (70) 2 (25)
Fractionation
3 fractions 183 (41.3) 19 (33.3) 0.510 3 (30) 0.533 1 (12.5) 0.163
5 fractions 187 (42.2) 27 (47.4) 6 (60) 6 (75)
8 fractions 73 (16.5) 11 (19.3) 1 (10) 1 (12.5)
Stage
T1N0 252 (56.9) 27 (47.4) 0.173 4 (40) 0.309 4 (50) 0.739
T2N0 191 (43.1) 30 (52.6) 6 (60) 4 (50)
Age (yr)a 72.7 (42–92) 70.7 (48–85) 0.060b 64.8 (48–79) 0.003b 72.9 (51–84) 0.890
Tumor-cell wall distance (mm)a 12.0 (0–58) 7.3 (0–34) 0.007b 6.0 (0–24) 0.158 1.9 (0–5) 0.000
Tumor diameter (mm)a 28.8 (9–80) 33.7 (13–70) 0.006 35.0 (20–49) 0.154 37.0 (6–70) 0.085b
PTV (cm3)a 32.5 (3–220) 48.7 (4–189) 0.007b 50.7 (22–81) 0.100b 73.7 (15–189) 0.125b
Risk factors per group, group with no pain n  443, chest wall pain (CWP) any grade n  57, severe CWP grade 3 n  10, rib fractures n  8. Each group is compared with
all subjects not belonging to that group. Shown p values are derived from the 2 test for nominal variables and independent sample t-test for continuous variables.
a Included in multivariate analysis.
b Significant p value in multivariate test (p  0.05).
PTV, planning target volume.
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moderate pain, up to 10% of postsurgical patients experience
severe, disabling pain.18 Severe pain in the postoperative setting
seems to be less common after video-assisted thoracoscopic
surgery than when patients undergo a thoracotomy.19
Although we identified risk factors for chest wall tox-
icity, the small number of rib fractures and grade 3 CWP
precludes us from drawing any firm conclusions. Tumor-
related risk factors for chest wall toxicity in this study were
target volume (PTV) and distance from the tumor to the chest
wall. Similar findings have been reported previously.11
Younger patients were more likely to suffer severe CWP, and
comorbidity did not significantly influence chest wall toxicity
in our analysis. Others have reported patient factors such as
obesity12 and continued smoking11 to predict for CWP, but
these data were unavailable in our patients.
Determining the role of SABR fractionation schemes in
chest wall toxicity is difficult to assess. Besides the total dose
delivered, the dose per fraction also determines the biological
impact of radiation in tumor and normal tissues. A radiobi-
ological model,14 the linear quadratic model (LQ model), is
available to calculate a biological equivalent dose of a certain
fractionation scheme. We converted the five- and eight-
fraction schedules toward three-fraction schedule of 20 Gy
using the LQ model. To avoid the problem, some published
studies did not account for this issue or elected to limit their
inclusion criteria to just one fractionation scheme.11–13 Dosi-
metric parameters predictive for developing chest wall tox-
icity have been explored by several authors.9–13,15 No thresh-
old dose or volume has been identified for CWP, but a
gradual increase in dose seems to increase the risk.9 However,
a high dose/small volume effect seems to be predictive for
rib fractures.13 We observed a trend that patients with rib
fractures received larger volume of 30 to 50 Gy and
maximum dose in the chest wall. Patients with severe pain
also received higher maximum doses in the chest wall
compared with mild to moderate CWP.
In all our patients, the chest wall was considered to be
an organ at risk during in the planning process, and hot spots
in the chest wall were avoided. Recently, the use of more
conformal SABR techniques such as volumetric modulated
arc therapy have been shown to further reduce chest wall
doses.20 This suggests that further reduction in chest wall
toxicity may not be inevitable when more tumors in the
proximity of the chest wall are treated using SABR. At
present, we are treating far larger tumors using SABR21 with
far higher chest wall doses as a consequence. The latter may
be a high-risk population that is more suited for such detailed
dosimetric studies.
A shortcoming of this study is that no histological
diagnosis was obtained in a majority of patients, largely due
to the poor condition of these mainly inoperable patients.
Previous reports5,22 about our study population have shown
that pretest probability of malignancy described by Herder et
al.23,24 based on CT imaging, 18F-fluorodeoxyglucose posi-
tron emission tomography, and comorbidity (i.e., COPD) was
94%. Other surgical series have shown that the chance of
treating benign disease in the Netherlands is below 5%.24–26
Furthermore, survival of patients in our region who were
treated without histopathological confirmation was not better
than those who did have pathological confirmation,22,27 a
finding that would argue against a high incidence of benign
disease.
In conclusion, SABR-induced chest wall toxicity is an
uncommon complication that is associated with risk factors
such as tumor diameter, treatment volume, and the distance
from the tumor to the chest wall.
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